益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化临床研究  

Clinical Study of Qi-Boosting and Liver-Softening Decoction Combined with Entecavir in the Treatment of Chronic Hepatitis with Liver Fibrosis

作　　者：周文锋[1] ZHOU Wen-feng(Anyang Fifth People's Hospital,Anyang,Henan,China,455000)

机构地区：[1]安阳市第五人民医院,河南安阳455000

出　　处：《河南中医》2020年第7期1058-1061,共4页Henan Traditional Chinese Medicine

基　　金：2019年河南省医学科技计划联合攻关项目(LHGJ20191278)。

摘　　要：目的:观察益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化的临床疗效。方法:选取2016年3月1日至2017年12月1日本院诊治的慢性肝炎肝纤维化患者60例,随机分为观察组和对照组,每组30例。对照组给予恩替卡韦治疗,观察组给予恩替卡韦联合益气软肝方治疗。结果:观察组治疗后白蛋白水平高于对照组,总胆红素、天冬氨酸氨基转移酶、丙氨酸氨基转移酶水平低于对照组,差异有统计学意义(P<0.05);观察组治疗后Ⅲ型前胶原、Ⅳ型胶原、血清透明质酸、层粘连蛋白低于对照组,差异有统计学意义(P<0.05);观察组有效率96.67%,对照组有效率73.33%,治疗组高于对照组,差异有统计学意义(P<0.05);观察组治疗后肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素(interleukin,IL)-10、IL-4、IL-6、肝硬度值低于对照组,差异有统计学意义(P<0.05);对照组不良反应发生率为10.00%,观察组不良反应发生率为6.67%,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:益气软肝方联合恩替卡韦治疗慢性肝炎肝纤维化,能改善患者肝功能、肝纤维化及炎症因子水平。Objective:To observe the clinical curative effect of Qi-Boosting and Liver-Softening Decoction combined with entecavir on chronic hepatitis with liver fibrosis.Methods:A total of 60 patients treated in our hospital with chronic hepatitis with liver fibrosis from March 1,2016 to December 1,2017 were selected and randomly divided into the observation group and the control group according to the random grouping method of even and odd-numbered license plates,with 30 cases in each group.The control group was treated with entecavir,while the observation group was treated with entecavir combined with Qi-Boosting and Liver-Softening Decoction.Results:After the treatment,the level of albumin in the observation group was higher than that in the control group,and the levels of total bilirubin,aspartate aminotransferase and alanine aminotransferase were all lower than those in the control group,and all the differences were statistically significant(P<0.05).The levels of procollagenⅢtype,collagenⅣtype,serum hyaluronic acid and laminin in the observation group were lower than those in the control group,and all the differences were statistically significant(P<0.05).The effective rate was 96.67%in the observation group,which was higher than 73.33%in the control group.The difference was statistically significant(P<0.05).The values of tumor necrosis factor(TNF-α),interleukin(IL)-10,IL-4,IL-6 and liver hardness in the observation group were lower than those in the control group,and all the differences were statistically significant(P<0.05).The incidence of adverse reactions was 10.00%in the control group and 6.67% in the observation group,and the difference was statistically significant(P<0.05).Conclusion:In terms of treating chronic hepatitis with liver fibrosis,Qi-Boosting and Liver-Softening Decoction combined with entecavir can improve the liver function,liver fibrosis and the level of inflammatory factors of patients.

关 键 词：慢性肝炎 肝纤维化 恩替卡韦 益气软肝方 

分 类 号：R259.752[医药卫生—中西医结合]